1-(1H-indol-5-yl)-3-(3-methyl-1,2-thiazol-5-yl)urea

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(1H-indol-5-yl)-3-(3-methyl-1,2-thiazol-5-yl)urea
• 化学式: C₁₃H₁₂N₄OS
• 分子量: 272.33
• InChiKey: KTCNJOSQCPZRRI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  98
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• 2-SUBSTITUTED-5-HYDROXY-4H-CHROMEN-4-ONES AS NOVEL LIGANDS FOR THE SEROTONIN RECEPTOR 2B (5-HT2B)
  申请人：VIRGINIA COMMONWEALTH UNIVERSITY

  公开号：US20170029399A1

  公开（公告）日：2017-02-02

  A family of compounds which function as selective ligands for the serotonin receptor 2B (5-HT 2B ) is identified. Some of the compounds are synthetic non-natural ligands which have a relatively strong interaction with 5-HT2B compared to naturally occurring compounds (some of which are identified for the first time herein as ligands for 5-HT 2B ). Because the compounds, both naturally occurring and synthetically produced, function as ligands for 5-HT 2B they will have application in, for example, the treatment and/or prevention of nervous system disorders such as Alzheimer's disease.
• COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY
  申请人：ZOGENIX INTERNATIONAL LIMITED

  公开号：US20170071949A1

  公开（公告）日：2017-03-16

  Formulations for and methods of treatment of Dravet syndrome that avoid side effects are disclosed. The formulations comprise a 5-HT receptor agonists which does not agonize selected 5-HT receptor subtypes, and in particular does not agonize the receptor subtype 5-HT2B. Also disclosed are combinations of such 5-HT receptor agonists. Also disclosed are combinations of such 5-HT receptor agonists and SSRIs, SNRIs, and triptans for treating co-morbidities associated with Dravet syndrome.
• US9884836B2
  申请人：——

  公开号：US9884836B2

  公开（公告）日：2018-02-06